Supplemental materials for the study entitled "Incidence of inpatient venous thromboembolism in treated rheumatoid arthritis patients and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting"
Supplemental data
Outcome, comorbidities, medical history and medications codes Disease Type Codes Rheumatoid arthritis 714.0 M05.xx or M06.xx 451.2, 451.9, 453.0, 453.1, 453.2, 453.3, 453.4, 453.8, 453.9, 451.81, 453.5, 453.9, 671.3, 671.4, 671.5, 415 22310-21495, 21800-21825, 23500-23515, 23570-23630, 23500-23515, 24500-24582, 24582, 24650-24685, 25500-25652, 26600-26615, 26720-26765, 27193-27248, 27267-27269, 27500-27540, 2750 CPT/HCP CS "99406" "99407" "G0436" "G0437"
Oral contraceptive use ICD-9 V25.xx ICD-10 Z30.xx ICD-9-procedure 65.6x, 66.2x, 66.3x, 66.5x, 66.69, 66.97 ICD-10-procedure 0U57xxx, 0UL7xxx, 0UT7xxx CPT 58300, 58301 HCPCS J1050, J7300, J7301, J7302, J7303, J7304, J7307, S4993, AA261, A4266, A4267, A4268 Drug abuse CPT/HCP CS "99408" "99409" "G0396" "G0397" "H0001" "H0002" "H0005" "H0006" "H0007" "H0008" "H0009" "H0010" "H0011" "H0012" "H0013" "H0014" "H0015" "H0016" "H0018" "H0019" "H0020" "H0021" "H0022" "H0047" "H0048" "H0049" "H0050" "H2034" "H2035" "H2036" "T1006" "T1007" Corticosteroi ICD- CPT/HCP CS "J1094" "J3300" "J3300" "J3302" "J3303" "J7622" "J7626" "J7627" "J7633" "J7634" "J7637" "J7638" "J7641" "J7683" "J7684" "J8540" "K0512" "K0513" "K0527" "K0528" "Q0137" "Q0138" "S0173" "S1090" "4135F" "4140F" NSAIDs CPT/HCP CS "G8895" "G9201" "G9435" "G9793" "4044F" "4070F" "C9279" "J1130" "J1741" "J1885" Salicylates CPT/HCP CS "G8895" "G9201" "G9435" "G9793" "4044F" "4070F"
Other NSAIDs CPT/HCP CS "C9279" "J1130" "J1741" "J1885"
Antiplatelet agents CPT/HCP CS "G8579" "G9438" "G8222" "G8224" "G9609" "4011F" "4073F" "C9460" "J0130" "J1327" "J3246" "J3364" "J3365" "C9109" "J3245" "C9460" "G8521" Thrombolytic agents CPT/HCP CS "G8696" "86590" "J0350" "J2993" "J2994" "J2995" "J2996" "J2997" "J3101" "C9002" "C9005" "J3100" Antithrombot ics CPT/HCP CS Anticoagulant s CPT/HCP CS category_dtl_code_desc in ("DME AND SUPPLIES" "MEDICATIONS" "NOT ASSIGNED" "OTHER THERAPEUTIC PROCEDURES") and "G8799" "G8967" "4075F" "A4800" "A4801" "C9107" "C9111" "C9121" "E1520" "J0583" "J0883" "J1642" "J1644" "J1645" "J1650" "J1652" "J1655" "J1945" "J7197" "Q2021" "Y5273" "99363" "99364" "93793" "S9336" "S9372" ICD-9-CM, ICD-10-CM, ICD-9 procedure, ICD-10 procedure, AHFSCLSS codes and CPT codes were used to corticosteroids, NSAIDs and anticoagulants Biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARD), conventional DMARD (cDMARD) in patients with rheumatoid arthritis Compared with intent-to-treat analysis approach, on-treatment approach is more conservative for the reasons below
Total number of VTE events D: Total number of patient-years : Incidence rate using treatment emergent AE approach X: Observed additional number of events using ever-exposure model Y: Additional number of patient-years using ever-exposure model + + : Incidence rate using ever-exposure model : Expected additional events assuming the incidence rate is consistent across time Conclusion: If the incidence rate of VTE decreases after drug discontinuation (a likely scenario if the drug is associated with VTE), the intention to treat model will underestimate the incidence rate while on-treatment approach will not (as − will always be greater than 0). 
